Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

The deubiquitinating enzyme USP19 modulates adipogenesis and potentiates high-fat-diet-induced obesity and glucose intolerance in mice.

Coyne ES., Bédard N., Gong YJ., Faraj M., Tchernof A., Wing SS.

Animal Study on Type 2 Diabetes, published in Diabetologia (2018) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Diabetologia (2018)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
30386869
DOI
10.1007/s00125-018-4754-4
Citations
27

Abstract (original English)

Aims/hypothesis Elucidating the molecular mechanisms of fat accumulation and its metabolic consequences is crucial to understanding and treating obesity, an epidemic disease. We have previously observed that Usp19 deubiquitinating enzyme-null mice (Usp19 -/- ) have significantly lower fat mass than wild-type (WT) mice. Thus, this study aimed to provide further understanding of the role of ubiquitin-specific peptidase 19 (USP19) in fat development, obesity and diabetes. Methods In this study, the metabolic phenotypes of WT and Usp19 -/- mice were compared. The stromal vascular fractions (SVFs) of inguinal fat pads from WT and Usp19 -/- mice were isolated and cells were differentiated into adipocytes in culture to assess their adipogenic capacity. Mice were fed a high-fat diet (HFD) for 18 weeks. Body composition, glucose metabolism and metabolic variables were assessed. In addition, following insulin injection, signalling activity was analysed in the muscle, liver and adipose tissue. Finally, the correlation between the expression of Usp19 mRNA and adipocyte function genes in human adipose tissue was analysed. Result Upon adipogenic differentiation, SVF cells from Usp19 -/- failed to accumulate lipid and upregulate adipogenic genes, unlike cells from WT mice. Usp19 -/- mice were also found to have smaller fat pads throughout the lifespan and a higher percentage of lean mass, com

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AdipogenesisAnimalsBlotting, WesternCross-Sectional StudiesDiet, High-FatEndopeptidasesGlucose IntoleranceGlucose Tolerance TestHumansMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research